---
title: "Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285078415.md"
description: "Oncolytics reported a 19.5-month median duration of response in second-line KRAS-mutant MSS metastatic colorectal cancer (mCRC) with its REO 022: pelareorep combination therapy, significantly exceeding the historical benchmark of 4-6 months. The objective response rate was 33%, three times higher than standard care rates. The company is enrolling for a randomized Phase 2 trial and is in discussions with the FDA for potential accelerated approval. Pelareorep has Fast Track designation for colorectal and pancreatic cancer, and Oncolytics is seeking strategic partnerships for further development."
datetime: "2026-05-04T13:13:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285078415.md)
  - [en](https://longbridge.com/en/news/285078415.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285078415.md)
---

# Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC

**Oncolytics reported a 19.5-month median duration of response in second-line KRAS‑mutant MSS metastatic colorectal cancer.**

**Key Highlights:**

-   REO 022: pelareorep combo showed 19.5-month median duration of response in 2L KRAS‑mutant MSS mCRC vs ~4–6 month historical benchmark.
-   Objective response rate of 33% with pelareorep, bevacizumab and FOLFIRI, ~3× higher than 6–11% standard‑of‑care rates.
-   Company is enrolling randomized Phase 2 in 2L RAS‑mutant MSS mCRC and engaging FDA on potential accelerated approval pathway.
-   Pelareorep has Fast Track designation for colorectal and pancreatic cancer; Company pursuing strategic partnerships to advance development.

Original SEC Filing: ONCOLYTICS BIOTECH INC \[ ONCY \] - 8-K - May. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)

## Related News & Research

- [Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer](https://longbridge.com/en/news/285077428.md)
- [Stocks in Play: Oncolytics Biotech Inc](https://longbridge.com/en/news/284230718.md)
- [Ipsen Reports First Head-to-Head Data Showing Dysport Provides Longer Symptom Control Than Botox](https://longbridge.com/en/news/287036494.md)
- [Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade | PPCB Stock News](https://longbridge.com/en/news/287069272.md)
- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)